Clinical Background
Babesiosis is a zoonosis caused by an intraerythrocytic parasite of the genus Babesia.
Epidemiology
- Prevalence
- Found in the Northeastern U.S. coast and upper midwestern states, the same region as agents responsible for Lyme disease and human granulocytic anaplasmosis (HGE)
- Simultaneous infections of babesiosis, Lyme disease and HGA occur at a rate of 10% of infected patients
- Transmission
- Tick bite (Ixodes spp)
- Vector – in the U.S., Ixodes scapularis (prior name of Ixodes dammini ) or more commonly known as a black-legged deer tick
- Blood transfusion (rarely)
- For more information on causal agents, life cycle and geographic distribution, see
CDC's information on Babesiosis
Organism
- Protozoal parasite – obligate parasite of red blood cells
- More than 100 known species – most common types are B. microti and B. divergens
Risk Factors for Severe Disease
- Splenectomy
- Immunosuppression
Clinical Presentation
- Most cases of human Babesia infection are asymptomatic
- Symptomatic patients experience fever, headache, nausea, sweats and rigors
- Symptoms occur 1 to 6 weeks following tick bite
- The resemblance to a fulminant malaria-like infection may complicate initial diagnosis
- Severe cases can result in hemolytic anemia and thrombocytopenia due to fragmentation of red blood cells by the parasite, resulting in capillary blockage in the spleen, liver, kidneys and central nervous system
- Immunocompromised patients may experience persistent or relapsing disease
- Complications
- Acute respiratory failure
- Congestive heart failure
- Renal failure
Treatment
- Generally treated for at least 7-10 days with a combination of two medications
- Atovaquone and azithromycin OR
- Clindamycin and quinine (for severely ill patients)
- Some severely ill patients may require supportive care
- Antipyretics to reduce fever
- Vasopressors to increase blood pressure if low
- Blood transfusions
- Exchange transfusions
- Mechanical ventilation
- Dialysis
Prevention
- Protection of body sites from tick exposure – long sleeves and pants when in tick-prone area
- DEET on exposed areas
Diagnosis
- Indications for testing – strong clinical suspicion with febrile illness and tick exposure or occupation with high risk
- Laboratory testing
- Giemsa-stained blood films (in patients from endemic areas)
- Diagnostic if parasites noted
- Relatively insensitive due to low level parasitemia in most patients
- IFA testing
- High sensitivity and specificity in Babesia detection
- Test of choice for laboratory diagnosis
- Rises 2-4 weeks after infection and wanes at 6-12 months
- PCR – highly sensitive and specific; relatively expensive test
Differential Diagnosis
- Malaria
- Lyme disease
- Rickettsial disease
- Ehrlichiosis
- Colorado tick fever
- Human granulocytic anaplasmosis (HGA)
- Brucellosis
- Dengue fever virus
Pharmacogenetics and Therapeutic Drug Monitoring
Indications for Laboratory Testing
- Tests generally appear in the order most useful for common clinical situations
- Click on number for test-specific information in the ARUP Laboratory Test Directory
| Test Name and Number |
Recommended Use |
Limitations |
Follow Up |
| Parasites Smear (Giemsa Stain), Blood 0049025 Method: Stain |
Use along with B. microti antibody in patients with history of travel or residence in endemic area Thick smears made from hemolyzed blood are the most useful for screening purposes in cases with low-level parasitemia; thin smears are used for parasite classification |
Although microscopic examination of thin smear blood samples is the accepted method for Babesia diagnosis, low parasitemia levels may hamper detection Time sensitive |
|
| Babesia microti Antibodies, IgG & IgM by IFA 0093048 Method: Indirect Fluorescent Antibody |
Detect B. microti-specific IgG and IgM antibodies in patient’s serum samples where there is a clinical suspicion of B. microti infection (patients with history of travel or residence in endemic area) |
|
|
Additional Tests Available
Click the plus sign to expand the table of additional tests.
| Test Name and Number | Comments |
| Babesia microti Antibody, IgG by IFA 0093049 Method: Indirect Fluorescent Antibody |
|
| Babesia microti Antibody, IgM by IFA 0093050 Method: Indirect Fluorescent Antibody |
|
General References
Krause PJ, McKay K, Gadbaw J, Christianson D, Closter L, Lepore T, Telford SR III, Sikand V, Ryan R, Persing D, Radolf JD, Spielman A. Increasing health burden of human babesiosis in endemic sites. Am J Trop Med Hyg. 2003; 68 (4) :431-436.PubMed
Comprehensive Review: July 2009
Last Update: November 2009